Comparative Cytotoxicity of C-1311 in Colon Cancer In Vitro and In Vivo Using the Hollow Fiber Assay

References

• Bonithon-Kopp C, Benhamiche AM. Are there several colorectal cancers? Epidemiological data. Eur J Cancer Prey 1999; 8 Suppl 1: S3–12.
   PubMedGoogle Scholar
• Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50 (1): 7–33.
   PubMed Web of Science ®Google Scholar
• Napier MP, Ledermann JA. Novel chemotherapeutic agents in colorectal cancer. Eur J Surg Oncol 2000; 26 (6): 605–610.
   PubMed Web of Science ®Google Scholar
• Waters J, Cunningham D. The changing face of chemotherapy in colorectal cancer. Br J Cancer 2001; 84 (1): 1–7.
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48 (7): 1722–1726.
   PubMed Web of Science ®Google Scholar
• Shimada Y, Rothenberg M, Hilsenbeck SG et al. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 1994; 5 (2): 202-206.
   Google Scholar
• Kawato Y, Furuta T, Aonuma M et al. Antitumor activi-ty of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28 (3): 192-198.
   Google Scholar
• Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leu-covorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19 (21): 4097–4106.
   Google Scholar
• Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1407–1412.
   Google Scholar
• Rothenberg ML, Eckardt JR, Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recur-rent colorectal cancer. J Clin Oncol 1996; 14 (4): 1128–1135.
   Google Scholar
• Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluo-rouracil-based chemotherapy. J Clin Oncol 1997; 15 (1): 251–260.
   Google Scholar
• Van Cutsem E, Cunningham D, Bokkel Huinink WW et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35 (1): 54-59.
   Google Scholar
• Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000; 18 (4): 343–354.
   PubMed Web of Science ®Google Scholar
• Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol 2004; 54 Suppl 1:S32–S39.
   PubMedGoogle Scholar
• Taieb J, Artru P, Paye F et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 2005; 23 (3): 502–509.
   Google Scholar
• Cholody WM, Martelli S, Paradziej-Lukowicz J, Konopa J. 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem 1990; 33 (1): 49–52.
   PubMed Web of Science ®Google Scholar
• Calabrese CR, Loadman PM, Lim LS et al. In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans. Drug Metab Dispos 1999; 27 (2): 240-245.
   Google Scholar
• Cholody WM, Martelli S, Konopa J. Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. J Med Chem 1992; 35 (2): 378–382.
   Google Scholar
• Burger AM, Double JA, Konopa J, Bibby MC. Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer 1996; 74 (9): 1369–1374.
   PubMed Web of Science ®Google Scholar
• Skladanowski A, Plisov SY, Konopa J, Larsen AK. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 1996; 49 (5): 772–780.
   PubMed Web of Science ®Google Scholar
• Burger AM, Jenkins TC, Double JA, Bibby MC. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 1999; 81 (2): 367–375.
   PubMed Web of Science ®Google Scholar
• Zaffaroni N, De Marco C, Villa R et al. Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. Eur J Cancer 2001; 37 (15): 1953-1962.
   Google Scholar
• Ishikawa T, Utoh M, Sawada N et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropy-rimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55 (7): 1091-1097.
   Google Scholar
• Skehan P, Storeng R, Scudiero D et al. New colorimet-ric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82 (13): 1107–1112.
   PubMed Web of Science ®Google Scholar
• Casciari JJ, Hollingshead MG, Alley MC et al. Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. J Natl Cancer Inst 1994; 86 (24): 1846–1852.
   Google Scholar
• Hollingshead MG, Alley MC, Camalier RF et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci 1995; 57 (2): 131–141.
   PubMed Web of Science ®Google Scholar
• Russo P, Malacarne D, Falugi C, Trombino S, O'Connor PM. RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53. Int J Cancer 2002; 100 (3): 266–275.
   PubMed Web of Science ®Google Scholar
• Mariadason JM, Arango D, Shi Q et al. Gene expres-sion profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003; 63 (24): 8791-8812.
   Google Scholar
• Kovach JS, Svingen PA, Schaid DJ. Levamisole poten-tiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase. J Natl Cancer Inst 1992; 84 (7): 515–519.
   PubMedGoogle Scholar
• Wiebke EA, Grieshop NA, Loehrer PJ, Eckert GJ, Sidner RA. Antitumor effects of 5-fluorouracil on human colon cancer cell lines: antagonism by levamisole. J Surg Res 2003; 111 (1): 63–69.
   PubMed Web of Science ®Google Scholar
• Sergent C, Franco N, Chapusot C et al. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins. Cancer Chemother Pharmacol 2002; 49 (6): 445–452.
   Google Scholar
• Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P. Sequence-dependent activity of the irinotecan-5FU combina-tion in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 1997; 73 (5): 729–734.
   PubMed Web of Science ®Google Scholar
• Van Hattum AH, Pinedo HM, Schluper HM, Hausheer FH, Boven E. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer 2000; 88 (2): 260–266.
   PubMed Web of Science ®Google Scholar
• Boyer J, McLean EG, Aroori S et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004; 10 (6): 2158-2167.
   Google Scholar
• Li L, Luan Y, Wang G et al. Development and charac-terization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med 2004; 14 (2): 257–264.
   Google Scholar
• Augustin E, Wheatley DN, Lamb J, Konopa J. Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells. Cancer Chemother Pharmacol 1996; 38 (1): 39–44.
   PubMed Web of Science ®Google Scholar
• Hyzy M, Bozko P, Konopa J, Skladanowski A. Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochem Pharmacol 2005; 69 (5): 801–809.
   PubMed Web of Science ®Google Scholar
• Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 2004; 11 (4): 413–424.
   PubMed Web of Science ®Google Scholar
• Cohen E, Ophir I, Shaul YB. Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci 1999; 112 ( Pt 16):2657–2666.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Fallis AG, Brown DL. Differential effects of taxol on two human cancer cell lines. Oncol Res 1997; 9 (5): 237–248.
   PubMed Web of Science ®Google Scholar
• Phillips RM, Pearce J, Loadman PM et al. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screen-ing programs. Cancer Res 1998; 58 (23): 5263–5266.
   Google Scholar
• Suggitt M, Cooper PA, Shnyder SD, Bibby MC. The hollow fibre model—facilitating anti-cancer pre-clinical phar-macodynamics and improving animal welfare. Int J Oncol 2006; 29 (6): 1493–1499.
   PubMed Web of Science ®Google Scholar
• Calabrese CR, Bibby MC, Double JA, Loadman PM. Pharmacokinetics and tissue distribution of the imidazoacridi-none C1311 in tumour-bearing mice. Cancer Chemother Pharmacol 1998; 42 (5): 379–385.
   PubMed Web of Science ®Google Scholar